BioCentury
ARTICLE | Deals

Via Mammoth deal, Vertex gains small CRISPR nucleases

CRISPR company pushes further into therapeutics

October 26, 2021 1:03 PM UTC

Vertex is expanding its gene editing capabilities again, this time via a deal with Jennifer Doudna-founded Mammoth that gives it access to some of the smallest CRISPR nucleases identified to date. 

The partners teamed up to develop in vivo gene editing therapies for two undisclosed indications based on the next-generation CRISPR gene editing that Mammoth Biosciences is developing. ...